6-(3-aminophenylamino)indolin-2-one | 887399-27-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-(3-aminophenylamino)indolin-2-one
• 英文别名: 6-(3-amino-phenylamino)-1,3-dihydro-indol-2-one；6-(3-aminophenylamino)-1,3-dihydroindol-2-one；6-((3-Aminophenyl)amino)indolin-2-one；6-(3-aminoanilino)-1,3-dihydroindol-2-one
• CAS: 887399-27-1
• 化学式: C₁₄H₁₃N₃O
• 分子量: 239.277
• InChiKey: IEFHMBNACJXCJG-UHFFFAOYSA-N

物化性质

• 沸点：
  494.4±45.0 °C(Predicted)
• 密度：
  1.333±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.2
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-(3-aminophenylamino)indolin-2-one 在 哌啶 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-morpholin-4-yl-N-[3-[[2-oxo-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-6-yl]amino]phenyl]-3-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models

  摘要：

  Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network. Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin. By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified. Optimization led to the identification of GNF-5837 (22), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF. The properties of 22 make it a good tool for the elucidation of TRK biology in cancer and other nononcology indications.

  DOI：

  10.1021/ml200261d
• 作为产物：
  描述：

  2-硝基-4-溴苯乙酸 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 溶剂黄146 为溶剂， 生成 6-(3-aminophenylamino)indolin-2-one
  参考文献：
  名称：

  Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models

  摘要：

  Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network. Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin. By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified. Optimization led to the identification of GNF-5837 (22), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF. The properties of 22 make it a good tool for the elucidation of TRK biology in cancer and other nononcology indications.

  DOI：

  10.1021/ml200261d

文献信息

• Compounds and Compositions as Protein Kinase Inhibitors
  申请人：Wan Yongqin

  公开号：US20080221192A1

  公开（公告）日：2008-09-11

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC kinases.

  本发明提供了一类新型化合物，包括该类化合物的药物组合物以及使用该类化合物治疗或预防与异常或失调激酶活性相关的疾病或障碍的方法，特别是涉及Abl、Bcr-Abl、cSrc、TPR-Met、Tie2、MET、FGFR3、Aurora、Axl、Bmx、BTK、c-kit、CHK2、Flt3、MST2、p70S6K、PDGFR、PKB、PKC、Raf、ROCK-H、Rsk1、SGK、TrkA、TrkB和TrkC激酶异常活化的疾病或障碍。
• Compounds and compositions as protein kinase inhibitors
  申请人：IRM LLC, a Delware Limited Corporation

  公开号：US08101608B2

  公开（公告）日：2012-01-24

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-II, Rsk1, SGK, TrkA, TrkB and TrkC kinases.

  本发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调激酶活性相关的疾病或障碍的方法，特别是涉及Abl、Bcr-Abl、cSrc、TPR-Met、Tie2、MET、FGFR3、Aurora、Axl、Bmx、BTK、c-kit、CHK2、Flt3、MST2、p70S6K、PDGFR、PKB、PKC、Raf、ROCK-II、Rsk1、SGK、TrkA、TrkB和TrkC激酶异常激活的疾病或障碍。
• COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
  申请人：Mi Yuan

  公开号：US20100168182A1

  公开（公告）日：2010-07-01

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly TrkA, TrkB, TrkC, PDGFR and c-kit.

  本发明提供了一种新型化合物类别，包括这种化合物的药物组成物和使用这种化合物治疗或预防与异常或失调的激酶活性有关的疾病或紊乱，特别是TrkA、TrkB、TrkC、PDGFR和c-kit的方法。
• WO2006/52936
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2008/73480
  申请人：——

  公开号：——

  公开（公告）日：——